Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab with or without ipilimumab versus placebo after nephrectomy in high-risk localized renal cell carcinoma
2016-004502-34Phase 3Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Apr 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Nivolumab monotherapy, Nivolumab + ipilimumab and Placebo (3 arms). Primary endpoint: Disease-free survival. Started Apr 2017; status: terminated.
02
Drugs
nivolumabipilimumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on 2016-004502-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004502-34.